Meeting
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
Presenter
Marshall R. Posner, MD
Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02945631, NCT01706939
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6058)
DOI
10.1200/JCO.2021.39.15_suppl.6058
Abstract #
6058
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Annual Meeting
The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.
Speaker: Marshall R. Posner, MD
Videos & Slides
2024 ASCO Annual Meeting
Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.
Speaker: Ari Joseph Rosenberg, MD
Speaker: Panel Discussion